KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Intangibles for 5 consecutive years, with $341.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Intangibles changed N/A year-over-year to $341.3 million, compared with a TTM value of $341.3 million through Jun 2025, changed N/A, and an annual FY2024 reading of $335.9 million, up 821.59% over the prior year.
  • Intangibles was $341.3 million for Q2 2025 at Recursion Pharmaceuticals, up from $335.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $341.3 million in Q2 2025 and bottomed at $1.3 million in Q4 2022.
  • Average Intangibles over 5 years is $119.6 million, with a median of $19.0 million recorded in 2022.
  • The sharpest move saw Intangibles dropped 5.7% in 2022, then skyrocketed 2690.43% in 2023.
  • Year by year, Intangibles stood at $1.4 million in 2021, then fell by 5.7% to $1.3 million in 2022, then surged by 2690.43% to $36.4 million in 2023, then skyrocketed by 821.59% to $335.9 million in 2024, then increased by 1.63% to $341.3 million in 2025.
  • Business Quant data shows Intangibles for RXRX at $341.3 million in Q2 2025, $335.9 million in Q4 2024, and $36.4 million in Q4 2023.